The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

Aprea Therapeutics, the US-based cancer treatment spinout of Karolinska Institute, yesterday increased its initial public offering to nearly $97.8m after underwriters took up the over-allotment option in full.
The company had issued 5.7 million shares priced at $15 each last week, raising $85m and seeing shares rise more than a third to close at $20.50 on the first day of trading.
Shares closed at $18.94 yesterday, but having consistently traded above the IPO price, joint-booking running managers…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in